clinical trial · NCT05603754
A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)
Biosplice Therapeutics, Inc.·phase3·completed·n = 496
Knee OsteoarthritisLorecivivintPlacebo
brief summary
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target (most painful) knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. This study will utilize standard outcomes to evaluate the safety and efficacy of lorecivivint.
started
Nov 18, 2022
primary completion
Feb 20, 2024
completion
Feb 20, 2024
last updated
Jul 25, 2024
official title
A Phase 3, 16-Week, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint 0.07 mg Dose in the Target Knee Joint of Subjects With Moderate to Severe Osteoarthritis Pain of the Knee
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol